Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 9 of 9 entries
View as:

A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04047290 Org: User:
Start: 09/20/19 End: 02/27/24 Due: 02/27/25

Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03261011 Org: User:
Start: 10/03/17 End: 04/13/23 Due: 04/13/24

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104

Phase: N/A Priority: Normal
NCT ID: NCT04349969 Org: User:
Start: 04/23/20 End: 11/08/22 Due: 11/08/23

Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03352531 Org: User:
Start: 01/02/18 End: 10/28/23 Due: 10/28/24

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT05021120 Org: User:
Start: 10/12/21 End: 05/27/25 Due: 05/27/26

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT04256174 Org: User:
Start: 06/15/20 End: 10/29/21 Due: 10/29/22

A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04516564 Org: User:
Start: 09/28/20 End: 06/21/21 Due: 06/21/22

A Study of AK111 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03622021 Org: User:
Start: 08/14/18 End: 09/09/19 Due: 09/09/20

Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT05048056 Org: User:
Start: 09/30/21 End: 05/17/23 Due: 05/17/24